Lymph nodes (LNs) are principal orchestrators of the adaptive immune response, yet in the context of malignancy, they are typically the first sites of metastasis. When tumors spread to LNs, they alter the immune repertoire, ultimately …
The standard of care for patients with resectable stage III/IV melanoma classically included upfront resection with adjuvant therapy. However, in more recent years, the amount of systemic therapies available for neoadjuvant use for these patients …
The concept of liquid biopsy analysis has been established more than a decade ago. Since the establishment of the term, tremendous advances have been achieved and plenty of methods as well as analytes have been investigated in basic research as …
Antigen-presenting cells (APCs) are pivotal mediators of immune responses. Their role has increasingly been spotlighted in the realm of cancer immunology, particularly as our understanding of immunotherapy continues to evolve and improve. There is …
Authors:
Cassia Wang, Lee Chen, Doris Fu, Wendi Liu, Anusha Puri, Manolis Kellis, Jiekun Yang
Small non-coding RNA or microRNA (miRNA) are critical regulators of eukaryotic cells. Dysregulation of miRNA expression and function has been linked to a variety of diseases including cancer. They play a complex role in cancers, having both tumour …
The molecular mechanisms underlying sensitivity and resistance to radiotherapy is an area of active investigation and discovery as its clinical applications have the potential to improve cancer patients’ outcomes. In addition to the traditional …
Melanoma is a highly immunogenic malignancy with an elevated mutational burden, diffuse lymphocytic infiltration, and one of the highest response rates to immune checkpoint inhibitors (ICIs). However, over half of all late-stage patients treated …
Authors:
Jamie Magrill, Dan Moldoveanu, Jiayao Gu, Mathieu Lajoie, Ian R Watson
Axillary management in patients with breast cancer is in a constant state of evolution. To provide appropriate treatment recommendations, we must understand the historical implications and the current indications for nodal staging as well as the …
Our laboratory previously pioneered the unbiased molecular characterization of blood circulating neoplastic cell populations isolated from patients diagnosed with metastatic breast cancer, eg, Lin-negative selected cells. This was achieved …
Glycosylation changes of cancer cells are known to be associated with malignant progression and metastases and potentially determine the organ-selective nature of metastasis as theorized by Paget (Lancet 1:571–573, 1889). Cellular glycans play a …
Lymphatic metastasis is the dominant route of initial spread for most solid tumors. For many such malignancies, including melanomas, surgical treatment previously included removal of all potentially draining regional lymph nodes (elective node …
Author:
Mark B. Faries
Open Access
09-12-2023 | Metastasis | Research Paper
Ketogenic diets (KDs) can improve the well-being and quality of life of breast cancer patients. However, data on the effects of KDs on mammary tumors are inconclusive, and the influence of KDs on metastasis in general remains to be investigated.
Authors:
Meret Grube, Arno Dimmler, Anja Schmaus, Rafael Saup, Tabea Wagner, Boyan K. Garvalov, Jonathan P. Sleeman, Wilko Thiele
Although the incidence of cutaneous melanoma (CM) has been increasing annually, the mortality rate has been decreasing, likely due to better prevention, earlier detection, improved surveillance, and the development of new therapies. Current …
Cancer is a disease that undergoes selective pressure to evolve during its progression, becoming increasingly heterogeneous. Tumoral heterogeneity can dictate therapeutic response. Transcriptomics can be used to uncover complexities in cancer and …
Authors:
Wendi Liu, Anusha Puri, Doris Fu, Lee Chen, Cassia Wang, Manolis Kellis, Jiekun Yang
Chemotherapy remains the primary treatment for most metastatic cancers. However, the response to chemotherapy and targeted agents is often transient, and concurrent development of resistance is the primary impediment to effective cancer therapy.
Breast cancer in young patients is known to exhibit more aggressive biological behavior and is associated with a less favorable prognosis than the same disease in older patients, owing in part to an increased incidence of brain metastases. The …
Authors:
Allison L. Hunt, Imran Khan, Alex M. L. Wu, Sasha C. Makohon-Moore, Brian L. Hood, Kelly A. Conrads, Tamara Abulez, Jonathan Ogata, Dave Mitchell, Glenn Gist, Julie Oliver, Debbie Wei, Monika A. Chung, Samiur Rahman, Nicholas W. Bateman, Wei Zhang, Thomas P. Conrads, Patricia S. Steeg
Patients with cutaneous melanoma can develop in-transit metastases (ITM), most often localized to limbs. For patients with uveal melanoma that develop metastatic disease, the overall majority develop isolated liver metastases. For these types of …
Authors:
Anne Huibers, Danielle K. DePalo, Matthew C. Perez, Jonathan S. Zager, Roger Olofsson Bagge
Lymphedema and specifically cancer-related lymphedema is not the main focus for both patients and physicians dealing with cancer. Its etiology is an unfortunate complication of cancer treatment. Although lymphedema treatments have gained an …
Authors:
Michael Bernas, Sara Al-Ghadban, Saskia R. J. Thiadens, Karen Ashforth, Walter C. Lin, Bauback Safa, Rudolf Buntic, Michael Paukshto, Alexandra Rovnaya, Margaret L. McNeely
This paper is a cross fertilization of ideas about the importance of molecular aspects of breast cancer metastasis by basic scientists, a pathologist, and clinical oncologists at the Henry Ford Health symposium. We address four major topics: (i) …
Authors:
S. David Nathanson, Lothar C. Dieterich, Xiang H-F. Zhang, Dhananjay A. Chitale, Lajos Pusztai, Emma Reynaud, Yi-Hsuan Wu, Alejandro Ríos-Hoyo
Most cancers and in particular carcinomas metastasise via the lymphatics to draining lymph nodes from where they can potentially achieve systemic dissemination by invasion of high endothelial blood venules (HEVs) in the paracortex [1, 2].
